Anavex Life Sciences’ Blarcamesine Shows Promise in Slowing Early Alzheimer’s...
Anavex Life Sciences, a clinical-stage biopharmaceutical company, has presented groundbreaking results from its Phase IIb/III trial of blarcamesine, or Anavex 2-73, for early Alzheimer’s disease at the 2024 Alzheimer’s Association...
